CD8A and neoplasm: In a recent work, an anti-CTLA-4 antibody combined with Doxil was highly effective at reducing the growth of B16 melanomas, and induced an increase in the CD8 T/Treg cells ratio in tumor-infiltrating lymphocytes, compared with nonliposomal treatments, without any significant side effects [68,69].